Asparaginase clearance: influence of the LDH-elevating virus

Lactate dehydrogenase-elevating virus, equine arteritis virus, and simian hemorrhagic fever virus: a new group of positive-strand RNA viruses

The last comprehensive reviews of nonarbotogaviruses included discussions on pestiviruses, rubella virus, lactate dehydrogenase-elevating virus (LDV), equine arteritis virus (EAV), simian hemorrhagic fever virus (SHFV), cell fusion agent, and nonarboflaviviruses. The inclusion of all these viruses in the family Togaviridae was largely based on the similarities in morphological and physical–chemical properties of these viruses, and in the sizes and polarities of their genomes. In the intervening years, considerable new information on the replication strategies of these viruses and the structure and organization of their genomes has become available that has led to the reclassification or suggestions for reclassification of some of them. The replication strategy of EAV resembles that of the coronaviruses, involving a 3'-coterminal nested set of mRNAs. Therefore, EAV has been suggested to be included in a virus superfamily, along with coronaviruses and toroviruses. Recent evidence indicates that LDV not only resembles EAV in morphology, virion and genome size, and number and size of their structural proteins, but also in genome organization and replication via a 3'-coterminal set of mRNAs. SHFV, although not fully characterized, exhibits properties resembling those of LDV and EAV, and the recent evidence suggest that it may possess the same genome organization as these viruses. The three viruses may, therefore, represent a new family of positive-strand RNA viruses and are reviewed together in this chapter. In this chapter, emphasis is on the recent information concerning their molecular properties and pathogenesis in vitro and in vivo and on the host immune responses to infections by these viruses.

Theoretical and practical considerations in the use of hemodialysis for the therapeutic removal of asparagine and other amino acids

The endogenous asparagine influx in mice undergoing asparaginase therapy can be neutralized by asparaginase activity equivalent to less than one IU/ml of plasma, as determined with a new, highly sensitive micro assay for asparaginase. It appears feasible that an asparagine influx of this magnitude may be cleared from the blood plasma by hemodialysis employing an artificial kidney apparatus with a clearance capacity somewhat greater than that routinely employed by renal patients. Application of this method for removing asparagine or other amino acids from the blood as an approach to cancer therapy ultimately depends upon the specific amino acid influx rates of the subject and upon the ability of the dialyzer to deplete the free amino acids in the blood plasma at a sufficiently high rate to lower specific amino acid concentrations in malignant tissues, or in adjoining interstitial spaces, to therapeutic levels. Based upon the data available, hemodialysis has potential therapeutic application as a means to control the removal of various free amino acids or other metabolic substrates from blood plasma.

Tumor inhibitory and non-tumor inhibitory L-asparaginases from Pseudomonas geniculata

Two enzymes that catalyze the hydrolysis of l-asparagine have been isolated from extracts of Pseudomonas geniculata. After initial salt fractionation, the enzymes were separated by chromatography on diethylaminoethyl-Sephadex and purified to homogeneity by gel filtration, ion-exchange chromatography, and preparative polyacrylamide electrophoresis. The enzymes differ markedly in physicochemical properties. One enzyme, termed asparaginase A, has a molecular weight of approximately 96,000 whereas the other, termed asparaginase AG, has a molecular weight of approximately 135,000. Both enzymes are tetrameric. The asparaginase A shows activity only with l-asparagine as substrate, whereas the asparaginase AG hydrolyzes l-asparagine and l-glutamine at approximately equal rates and it is also active with d-asparagine and d-glutamine as substrates. The asparaginase A was found to be devoid of antitumor activity in mice, whereas the asparaginase AG was effective in increasing the mean survival times of both C3H mice carrying the asparagine-requiring Gardner 6C3HED tumor line and Swiss mice bearing the glutamine-requiring Ehrlich ascites tumor line. These differences in antitumor activity were related to differences in the K(m) values for l-asparagine for the two enzymes. The asparaginase A has a K(m) value of 1 x 10(-3) M for this substrate whereas the corresponding value for the AG enzyme is 1.5 x 10(-5) M. Thus the concentration of asparagine necessary for maximal activity of the asparaginase A is very high compared with that of the normal plasma level of asparagine, which is approximately 50 muM.

Enhanced plasma persistence of therapeutic enzymes by coupling to soluble dextran

Conjugation of carboxypeptidase G and arginase, two enzymes of therapeutic interest, to a soluble dextran significantly enhanced plasma persistence in normal and tumour-bearing mice. A prolonged decrease in arginine concentrations in plasma of tumour-bearing mice was demonstrated by using the dextran-linked arginase. Gel filtration of dextran-enzyme conjugate showed that enzyme activity co-chromatographed as a single peak with carbohydrate, and enzyme was shown to be covalently linked to the dextran.

Purification and properties of L-glutaminase-L-asparaginase from Pseudomonas acidovorans

An enzyme that catalyzes the hydrolysis of both glutamine and asparagine has been purified to homogeneity from extracts of Pseudomonas acidovorans. The enzyme having a ratio of glutaminase to asparaginase of 1.45:1.0 can be purified by a relatively simple procedure and is stable upon storage. The glutaminase-asparaginase has a relatively high affinity for L-asparagine (Km=1.5 X 10(-5) M) and L-glutamine (Km=2.2 X 10(-5) M) and has a molecular weight of approximately 156,000 the subunit molecular weight being approximately 39,000. Injections of the enzyme produced only slight increases in the survival time of C3H/HE mice carrying the asparagine-requiring 6C2HED Gardner lymphoma and of white Swiss mice carrying the glutamine-requiring Ehrlich lymphoma.

Antibody-producing cells: virus-induced alteration of response to antigen

Spleen antibody-forming cells of mice yield a 3- to 10-fold increase in their response to sheep erythrocyte antigen if they are acutely infected by lactate dehydrogenase-elevating virus. This early stimulation is replaced by a long-term inhibition of the antibody-forming cells as the viremia goes into its persisting chronic stage. These contrasting immunological phenomena are examined as contributing factors responsible for the enhancement by this virus of asparaginase (EC 3.5.1.1; L-asparagine amidolydrolase) therapy against leukemia in mice, and for the alteration of the susceptibility of mice to various neoplastic processes.

Inhibition of antibodies to nuclear antigen and to DNA in New Zealand mice infected with lactate dehydrogenase virus

New Zealand mice developed antibodies to nuclear antigen leading to immune-complex nephritis. Humoral antibody was directed primarily against denatured DNA, although antibody to native DNA was also found. Persistent infection with lactate dehydrogenase virus significantly lowered antibodies both to nuclear antigen and to DNA in these mice. In addition, female (NZB x W)F(1) mice infected with lactate dehydrogenase virus were protected from the usual nephritic death occurring after the trapping of complexes of nuclear antigen and its antibody and of DNA and its antibody in the glomerular filter.